share_log

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

Benzinga Real-time News ·  Aug 12, 2022 04:56
Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment